Interview

FDA Focus: What Lowenstein's Practice Chair Is Watching

Law360 (August 10, 2018, 4:33 PM EDT) -- Lowenstein Sandler LLP’s James Shehan, chair of the firm’s U.S. Food and Drug Administration practice, tells Law360 he's tracking patent litigation over biosimilars, watching for new off-label promotion policies and eyeing innovative approaches to clinical trials.

James Shehan Shehan, who joined Lowenstein two years ago in its New York City office, has a resume that includes in-house stints as general counsel at Novo Nordisk and corporate counsel at Pfizer Inc.

He has also been in private practice at FDA boutique Hyman Phelps & McNamara PC, and early in his career, Shehan was an associate at Sutherland Asbill & Brennan LLP and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS